CollPlant Biotechnologies (CLGN)

• Market cap: $27.7M
• 1 day: 0.00%
• 5 days: 0.41%
• 1 month: -23.90%
• 3 months: -39.95%
• 6 months: -43.46%
• Year to date: -36.48%
• 1 year: -53.82%
• 5 years: -77.28%
• 10 years: -67.73%
• Sector: Healthcare
• Industry: Biotechnology

About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Employees: 57

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

8% more funds holding

Funds holding: 13 [Q3] → 14 (+1) [Q4]

0.34% more ownership

Funds ownership: 10.78% [Q3] → 11.12% (+0.34%) [Q4]

32% less capital invested

Capital invested by funds: $6.79M [Q3] → $4.59M (-$2.21M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $14 479% upside
• Avg. target: $14 479% upside
• High target: $14 479% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target

479% upside $14

Buy Maintained

27 Mar 2025